431 related articles for article (PubMed ID: 11711607)
1. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.
Hezareh M; Hessell AJ; Jensen RC; van de Winkel JG; Parren PW
J Virol; 2001 Dec; 75(24):12161-8. PubMed ID: 11711607
[TBL] [Abstract][Full Text] [Related]
2. Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.
Leoh LS; Daniels-Wells TR; Martínez-Maza O; Penichet ML
Mol Immunol; 2015 Oct; 67(2 Pt B):407-15. PubMed ID: 26232328
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
[TBL] [Abstract][Full Text] [Related]
4. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.
Posner MR; Elboim HS; Cannon T; Cavacini L; Hideshima T
AIDS Res Hum Retroviruses; 1992 May; 8(5):553-8. PubMed ID: 1381201
[TBL] [Abstract][Full Text] [Related]
5. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
6. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
Front Immunol; 2021; 12():733958. PubMed ID: 34566999
[TBL] [Abstract][Full Text] [Related]
7. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
8. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
9. Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity.
Goldberg BS; Kaku CI; Dufloo J; Bruel T; Schwartz O; Spencer DA; Hessell AJ; Ackerman ME
mBio; 2021 Oct; 12(5):e0174321. PubMed ID: 34634936
[TBL] [Abstract][Full Text] [Related]
10. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.
Moldt B; Shibata-Koyama M; Rakasz EG; Schultz N; Kanda Y; Dunlop DC; Finstad SL; Jin C; Landucci G; Alpert MD; Dugast AS; Parren PW; Nimmerjahn F; Evans DT; Alter G; Forthal DN; Schmitz JE; Iida S; Poignard P; Watkins DI; Hessell AJ; Burton DR
J Virol; 2012 Jun; 86(11):6189-96. PubMed ID: 22457527
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
12. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.
Moldt B; Schultz N; Dunlop DC; Alpert MD; Harvey JD; Evans DT; Poignard P; Hessell AJ; Burton DR
J Virol; 2011 Oct; 85(20):10572-81. PubMed ID: 21849450
[TBL] [Abstract][Full Text] [Related]
13. Fc receptor but not complement binding is important in antibody protection against HIV.
Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
[TBL] [Abstract][Full Text] [Related]
14. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.
van Erp EA; Luytjes W; Ferwerda G; van Kasteren PB
Front Immunol; 2019; 10():548. PubMed ID: 30967872
[TBL] [Abstract][Full Text] [Related]
15. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.
Arduin E; Arora S; Bamert PR; Kuiper T; Popp S; Geisse S; Grau R; Calzascia T; Zenke G; Kovarik J
Mol Immunol; 2015 Feb; 63(2):456-63. PubMed ID: 25451975
[TBL] [Abstract][Full Text] [Related]
16. Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".
Sun Z; Li J; Hu X; Shao Y; Zhang MY
Antiviral Res; 2015 Jun; 118():1-9. PubMed ID: 25770672
[TBL] [Abstract][Full Text] [Related]
17. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
18. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
19. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.
Lo M; Kim HS; Tong RK; Bainbridge TW; Vernes JM; Zhang Y; Lin YL; Chung S; Dennis MS; Zuchero YJ; Watts RJ; Couch JA; Meng YG; Atwal JK; Brezski RJ; Spiess C; Ernst JA
J Biol Chem; 2017 Mar; 292(9):3900-3908. PubMed ID: 28077575
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
Matsushita S; Maeda H; Kimachi K; Eda Y; Maeda Y; Murakami T; Tokiyoshi S; Takatsuki K
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1107-15. PubMed ID: 1380258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
